in vaccinated patients was significantly correlated with increased PFS. Subsequent studies will seek to enhance T cell activity by combining with anti-PD-1.
Introduction
HER2 is overexpressed in 20-30% of breast cancers, and is associated with more aggressive tumor behavior (1) . Treatment of HER2 overexpressing tumors has been revolutionized by therapies targeting HER2. Treatment with single agent HER2-targeted therapy (trastuzumab and T-DM1), combinations of chemotherapy and HER2-targeted therapy, and more recently, combinations of HER2-targeted therapies (trastuzumab plus pertuzumab or trastuzumab plus lapatinib) have lengthened progression free (PFS) and overall survival (OS) in the metastatic setting (2-4). However, additional therapies are clearly needed as the majority of metastatic HER2+ patients will eventually progress on these agents. While treatment with immune checkpoint blockade (ICB) has shown activity in other molecular subtypes of breast cancer like triple negative breast cancer (5, 6) , HER2 overexpressing tumors have lower response rates to ICB (7) . This may be due to fewer somatic mutations and therefore fewer tumor neoepitopes, but even treatment-refractory tumors generally continue to overexpress HER2 (8) . It is also recognized that HER2-specific immunity is lost throughout the progression of HER2+ disease (9) . Accordingly, there is great interest in enhancing adaptive immune responses to HER2, including cancer vaccines that activate broad, HER2-specific T cell and antibody responses, and how such therapeutics can be integrated into the current management of metastatic HER2+ that immune responses against HER2 may be associated with an improved clinical outcome (11) (12) (13) (14) (15) . In our previous studies, vaccine-induced antibodies elicited various anti-tumor activities, including increased internalization of the target antigen, antiproliferative effects, and antibody dependent cellular cytotoxicity (ADCC) (16, 17) .
Among viral vectors, alphavirus-like replicon particles (VRP), based on attenuated Venezuelan equine encephalitis (VEE) virus, are especially attractive because of their high expression of heterologous proteins, targeted expression in and maturation of dendritic cells, and induction of robust humoral and cellular immune responses to the vectored gene products (18) (19) (20) (21) . Foreign genes can be inserted in place of the VEE structural protein gene region in the cDNA plasmid, and an RNA transcript, when introduced into dendritic cells, will replicate. This self-amplifying replicon RNA will direct the synthesis of large amounts of the foreign gene product within the cell, typically reaching levels of 15-20% of total cell protein (22). They also activate immune responses against the encoded foreign gene product despite the development of neutralizing antibodies against the viral particle (18).
We previously performed a phase I clinical trial of a novel alphavirus vector encoding the tumorassociated antigen carcinoembryonic antigen (CEA) (VRP-CEA(6D)), in metastatic cancer patients (23). There was no dose limiting toxicity and the highest dose tested (4x10 8 IU) was determined to be the maximal feasible dose. CEA-specific T cell and antibody responses following VRP-CEA(6D) vaccination were observed regardless of the development of neutralizing antibodies. We chose a dose level of 4x10 8 IU viral replicon particles for the current 7 study because it induced consistent activation of T cell and antibody responses in our previous study (23).
Here, we developed an alphaviral vector-based vaccine encoding the extracellular (ECD) and transmembrane (TM) domains of HER2 (VRP-HER2). We tested the safety, immunogenicity, and efficacy of this vaccine in preclinical murine models and in patients with advanced HER2-overexpressing breast cancers either alone or with concurrent HER2-targeted therapy. We demonstrated that the vaccine was safe, tolerable, and successfully induced T cell and polyfunctional antibody responses in our preclinical model and in humans with advanced HER2+ breast cancer. Strikingly, we identified an expanded perforin expressing memory CD8 T cell population that was significantly associated with improved PFS, indicating a possible biomarker for future studies.
Research. Parental or hHER2-expressing NMUMG cells were plated overnight in 96-well plates (Corning).
Serum was diluted and added to plates for 1 hour. Plates were washed and cells were fixed with 1% formalin. A secondary anti-mouse IgG-HRP conjugated antibody (Cell Signaling) was used prior to developing with TMB substrate (Biolegend) and absorbance determined using a Bio-Rad Model 680 microplate reader (Bio-Rad).
ELISPOT
Mouse IFN- ELISPOT assay (Mabtech Inc.) was performed according to manufacturer's instructions. Briefly, splenocytes (500,000 cells/well) were incubated in RPMI-1640 medium (Invitrogen) with 10% FBS for 24 hours. Cells were stimulated with HER2 pooled peptides (1 g/ml; JPT, Germany), empty VRP vector, or irrelevant HIV-gag peptide mix (1 g/ml: JPT, Germany). PMA (50 ng/ml) and Ionomycin (1g/ml) (Sigma) were used as positive controls. All values are shown corrected for background, with spots from HIV control wells subtracted.
Flow Cytometry and peptide restimulation
For flow cytometry, cells were isolated from mouse spleens and mechanically dissociated with a 40-µm cell strainer (Greiner Bio-One). Red blood cells were lysed with RBC lysing buffer (Sigma). Cells were plated in 96-well plates (Corning) (1x10 6 cells/well) with brefeldin A (Biolegend), monensin (Biolegend), CD107a (1D4B), and CD107b (ABL-93; both BD Biosciences at 0.1 g/well) in the presence or absence of a pool of HER2 peptides for 6 hours as previously described (29). Cells were stained with Fixable viability dye (Invitrogen) and additional fluorochrome-conjugated antibodies. For intracellular staining, a FoxP3 Fix/Perm kit was used according to the manufacturer's instructions (eBioscience). Antibodies used include:
Research. 
Patients and study drug administration
The phase I clinical trial was performed under an FDA-approved Investigational New Drug Exemption and registered at ClinicalTrials.gov (NCT01526473). Participants were recruited from medical oncology clinics at Duke University Medical Center, Durham, NC and provided written consent under a protocol approved by the Duke University Medical Center Institutional Review Board. This study was conducted in accordance with all recognized institutional and federal guidelines including those put forth in the Declaration of Helsinki.
Eligibility requirements included age >18, stage IV, HER2-overexpressing (2+, 3+) or FISH+ malignancy, and progressive or locally recurrent disease despite having received at least 1 prior FDA-approved HER2-targeted therapy (e.g. trastuzumab, trastuzumab plus pertuzumab, T-DM1, or lapatinib), ECOG status of 0 or 1, adequate hematologic counts, hepatic and renal function, and a left ventricular ejection fraction (LVEF) of >50%. Known autoimmune disease, immunosuppressive therapies or HIV, significant cardiovascular disease or arrhythmias were exclusionary criteria.
There were two treatment cohorts (Sup Figure S1 ). Cohort 1 evaluated vaccination with VRP-HER2 alone and cohort 2 evaluated vaccination with VRP-HER2 during concurrent anti-HER2 therapy chosen by their attending medical oncologist. Concurrent bisphosphonates and hormonal therapy were permitted in both cohorts. Discontinuation of prior chemotherapy or targeted therapy was required for at least three weeks before the first VRP-HER2 administration in cohort 
CYTOF Flow Cytometry analysis
Research.
on within three days of staining and were analyzed using Spanning-tree Progression Analysis of Density-normalized Events (SPADE) (32) in Cytobank (Mountain View, CA). FCS files were normalized through median bead intensity and beads were removed prior to analysis (33) .
SPADE Analysis.
The spanning-tree progression analysis of density-normalized events (SPADE) algorithm was used to identify clusters of cells that were organized into a SPADE tree (Sup Figure S3 ). Cell surface markers were used to create the SPADE clusters and were pregated on live, intact singlets. Once clusters had been made, effector molecule expression pre-and postvaccination within these clusters was analyzed. Significant differences in median expression levels were determined using a two-sided paired t test with multiple hypothesis test correction with a family-wise error rate (FWER). For each stimulation condition, the random permutation was performed 100 times, and all significance tests were repeated for each permutation. For each permutation, the minimum p value from all of these significance tests was recorded, and the 5th percentile of this distribution of minimum p values was used as a significance cutoff for the stimulation condition and clustering method.
Statistical analyses
Data are presented as mean ± standard error of the mean (SEM). Student's t test was used for experiments with only 2 groups. Tumor volumes were analyzed at the terminal endpoint only, unless otherwise indicated. Statistical analysis was performed using Prism (GraphPad). P values of 0.05 or less were considered statistically significant. Not all significant differences are shown in every graph. *p < 0.05; **p < 0.01; ***p < 0.001
For clinical studies, PFS interval was defined as the time from trial enrollment to disease progression or death, whichever came first. OS was defined from the time of enrollment until death due to any cause. PFS and OS were calculated using the Kaplan-Meier product limit method. Radiographic response was determined according to RECIST criteria 1.1. A paired Student's t test was used to determine differences pre-and post-vaccination.
Results

VRP-HER2 generates robust anti-HER2 response
We developed a VRP-based vaccine expressing the ECD and TM domains of human HER2 (VRP-HER2). Standard toxicology analysis detected no systemic or organ specific toxicities in VRP-HER2 vaccinated, HER2-transgenic mice (data not shown). Following vaccination, induction of both VRP-and HER2-specific T cell responses was detected in splenocytes using an IFN--ELISPOT assay after restimulation with empty VRP vector or HER2 peptides ( Figure   1A ). Similarly, high titers of HER2-specific antibodies ( Figure 1B ) that bound HER2-expressing cells were induced by VRP-HER2 vaccination. These data demonstrate that the VRP-HER2 vaccine breaks tolerance to HER2 and induces potent anti-HER2 immune responses.
We tested the antitumor effect of VRP-HER2 immunization in vivo. In both prevention (vaccine given 2 weeks prior to tumor implantation) and treatment (vaccine given the day after tumor implantation) models, there was sustained control of tumor growth compared with control VRP-CEA vaccination (vaccine given 2 weeks prior) and unvaccinated mice ( Figure 1C ). In addition, mice receiving VRP-HER2 that had cleared their primary tumor challenge were all resistant to subsequent tumor rechallenge ( Figure 1C ). Given this evidence for a sustained memory response, we analyzed splenocytes for responsiveness to restimulation with HER2 peptides by IFN--ELISPOT ( Figure 1D ) and found that HER2-specific T cell responses were present in all mice that were implanted with a HER2-expressing tumor due to immune responses against HER2
presented by tumor cells in these mice. We further evaluated the quality of long term memory only the VRP-HER2 vaccinated mice contained a systemic population of expanded, activated HER2-specific cytolytic CD8+ T cells ( Figure 1E ). No changes in CD4 memory T cell frequency or functionality in response to HER2 peptide restimulation was observed (data not shown).
Serum from VRP-HER2 vaccinated mice contained a significantly higher titer (P<0.005) of anti-HER2 antibodies than unvaccinated or control VRP-CEA vaccinated mice ( Figure 1F ), further supporting the formation of long lasting HER2-specific memory responses. These data demonstrate that VRP-HER2 is able to provide significant anti-tumor protection by eliciting both T and B cell responses to HER2. These data further supported the initiation of a phase I study in humans with advanced HER2 over-expressing malignancies.
Patient demographics
Patients (n=22) were enrolled at one center from 10/21/2012 to 10/19/2015. Four patients were enrolled and received treatment in cohort 1 (no concurrent HER2-targeted therapy) and eighteen in cohort 2 (combined with HER2 targeted therapy) (Sup Figure S1 ). Demographics for cohorts 1 and 2 are listed for each patient ( Table 1) . The majority of patients had substantial metastatic disease burden (median of 2 sites including lung and liver) and had been heavily pretreated (median of 3.5 prior lines of therapy), all having progressed on prior trastuzumab, 13/22 (59.1%) having progressed on a lapatinib-containing regimen, 8/22 (36.3%) having progressed on a pertuzumab-containing regimen, and 9/22 (40.9%) having progressed on a T-DM1-containing regimen (Table 1) . Additionally, the median duration of metastatic disease at the time of enrollment was 31 months. In cohort 2, concurrent regimens during the immunization schedule included: TDM-1 (6/18; 33.3%) patients, trastuzumab/pertuzumab (5/18; 27.8%) patients, 
trastuzumab/lapatinib (3/18; 16.7%), single agent trastuzumab (3/18; 11.1%) and single agent lapatinib (1/18; 5.6%). All 22 enrolled patients completed all 3 vaccinations. In addition, in cohort 2, two patients were receiving concurrent anti-endocrine therapy, one of these patients was receiving the aromatase inhibitor Letrozole and the other was receiving the SERD Faslodex.
VRP-HER2 vaccination alone (cohort 1) and in combination with anti-HER2 therapies (cohort 2) was well tolerated and with no dose limiting toxicity ( Table 2 ). There were four grade 3 adverse events (AEs) but none were deemed to be related to VRP-HER2. Two Grade 2 AEs (fatigue and decreased white blood cell count) were deemed possibly related to VRP-HER2. The remainder of the AEs deemed related to the VRP-HER2 were Grade 1 and included: diarrhea (definite), pustular rash (definite), oral mucositis (definite), malaise (possible), nausea (possible), dry mouth (possible), sore throat (possible), decreased neutrophil count (possible), and decreased white blood cell count (possible). The remaining AEs were felt to be unrelated. One patient withdrew consent for participation after receiving injection #3 on week 4, but did not report any AEs.
Because the anti-HER2 antibody trastuzumab can be associated with cardiotoxicity, left ventricular ejection fraction (LVEF) was measured prior to starting vaccination and at week eight. No symptomatic heart failure or significant decrease in LVEF of 16 or more percentage points from baseline or 10 to 15 percentage points from baseline to below the lower limit of normal was observed for any enrolled patient at any time point on trial.
Induction of T cell responses by VRP-HER2
on
To evaluate any systemic changes in T cell responses post-vaccination, peripheral blood mononuclear cells (PBMCs) from baseline and six weeks after the initial vaccination were evaluated by multiparameter mass cytometry in 13 of the patients in cohort 2. This technique allowed us to maximize our analysis of these samples by staining with a panel of 34 surface markers and cytokines (Sup Table S1 ). Cells were restimulated with a pool of HER2 peptides and stained to evaluate the impact of vaccination on HER2-specific immunity. Live, intact single cells were clustered using cell surface markers into a SPADE tree that identified major immune cell subsets (Sup Figure S3) . Expression of effector molecules following HER2 peptide restimulation of PBMCs taken pre-and post-vaccination within these clusters was analyzed and one cluster had a significant increase in the expression of perforin following vaccination. This cluster was identified as containing effector/effector memory CD8 T cells. viSNE plots colored by various cell surface markers confirm the identify of this cluster by the high expression of CD3, CD8, CD107a, and the low expression of CD4 and CD20 (Figure 2A ). Additionally, a subset of the cluster expresses high levels of CD45RA, whereas the rest do not, indicating a mixture of CD8 effector and memory T cells (Figure 2A) . A heat map of expression of all surface markers by each of the identified SPADE clusters further shows that this cluster (shown in the top row) is negative for CCR7 and CD28 while expressing high levels of CD57, further distinguishing it from naïve CD8 T cells ( Figure 2B ).
Within this cluster, median expression of perforin was significantly higher in restimulated (red; 9/13; 69.2%) ( Figure 2C and Sup Figure S4 ). The same analysis performed on unstimulated PBMC samples did not reveal any significant changes in perforin expression highlighting the HER2 specificity of this response post-vaccination (data not shown). Furthermore, analysis of the other effector molecules in all clusters post-vaccination did not reveal any additional significant changes. Of note, one of our clusters was identified as a potential CD4+ Treg population based on high CD25 expression ( Figure 2B ). When the number of cells within this cluster was evaluated pre-and post-vaccination, there were patients that had no change, an increase, or a decrease in Tregs following vaccination (Sup Figure S5A) .
Induction of antibody responses by VRP-HER2
In our previous VRP-CEA study (34), we observed viral replicon particle (VRP-induced neutralizing antibodies as defined by the ability of serum from vaccinated patients to prevent VRP from infecting a permissive cell line. In the current study, neutralizing antibodies against VRP were again detected at high levels after immunization ( Figure 3A) . Despite the presence of neutralizing antibody, we were able to also detect HER2-specific antibodies in the serum of vaccinated patients. Although the overall levels of HER2-specific antibodies were low, VRP-HER2 induced a detectable increase in HER2-specific antibodies in 15/17 (88.2%) patients with available serum specimens post-vaccination ( Figure 3B) . Because of the extensive use of trastuzumab in this patient population, we modified our cell-based ELISA to allow us to assess antibody responses to HER2 epitopes other than the trastuzumab and pertuzumab binding sites.
We stably transfected EPH4 cells, a murine breast epithelial cell line that lacks endogenous pertuzumab but is still recognized by antibodies generated in mice following vaccination against hHER2 (Sup Figure S2 ). Using this cell line, we also observed an increase in nontrastuzumab/pertuzumab HER2-specific antibodies in 14/17 (82.4%) patients tested post vaccination ( Figure 3C ). The overall levels of antibodies present were low, but indicate an expansion of HER2-specific humoral responses above background trastuzumab/pertuzumab levels.
Functionality of antibodies induced by VRP-HER2
Many standard of care (SOC) treatments for advanced HER2+ breast cancer include the use of monoclonal antibodies against HER2. An advantage to our vaccine approach is that in addition to stimulating a T cell response, we can also induce polyclonal, polyfunctional anti-HER2
antibodies. In order to study the functionality of these vaccine-induced antibodies, we first determined whether they can mediate ADCC. To study ADCC, we combined patient serum with healthy donor PBMC and a CEM.NKR cell line expressing HER2, which is resistant to nonspecific NK killing (24). In 10/18 (55.6%) subjects, the serum from post VRP-HER2 immunization induced a greater degree of ADCC than prior to vaccination ( Figure 3D ).
Individual killing data for the subjects that induced the greatest degree of ADCC following immunization is shown ( Figure 3E ). Despite the presence of trastuzumab and/or pertuzumab, which can both mediate ADCC (35, 36) , in the serum of these patients, the increase in ADCC activity following the immunizations suggests that additional ADCC capable antibodies were induced by vaccination. 
Clinical Outcomes
In cohort 1, there were no responses and the median PFS was 1.8 months and the median OS was 50.2 months ( Figure 4A ). In cohort 2, there was one partial response (PR) and 7 with initially Figure 2C ) there was a significantly longer PFS than among those who did not ( Figure 4B ). These data demonstrate that the induction of a HER2-specific memory CD8 T cell population following vaccination may represent a biomarker for immune responsiveness and beneficial clinical outcomes. The small sample size did not allow for any trends to be identified in the relationship between the induction of this perforin expressing population and the specific concurrent HER2 targeted therapies each patient was being given (Sup Table S2 ). This is a relationship that we will follow up on in our future studies. We attempted to find a correlation between any of the antibody responses and clinical outcome, but none were statistically significant, possibly due to the small number of patients and concurrent therapy with trastuzumab in the majority of the patients which made detection of small clinical changes difficult to identify. Interestingly, when we evaluated the impact of changes in Treg populations post-vaccination, patients that had a decrease in Tregs had a significantly improved overall survival (Sup Figure S5B) . This is another potential biomarker that can be further validated in larger studies. perhaps reflecting a less robust adaptive immune response in HER2 driven breast cancer (9) .
Discussion
Rather than relying on enhancing the naturally occurring adaptive immune response to tumor neoepitopes, we developed an immunization strategy that would expand HER2-specific T cells and antibodies to provide effective anti-tumor responses that complement current HER2 targeting SOC regimens.
It will be of significance to better understand how different SOC therapies for patients with HER2+ BC may interact with VRP-HER2 vaccination. Multiple studies have documented the ability of HER2 antibodies to elicit different types of immune responses (42) , which may synergize with HER2 vaccination. Additionally, many HER2+ BC patients are also ER+ and undergoing various anti-endocrine therapies, but while some studies have suggested that that estrogen signaling can alter immunity (43, 44) , other studies suggest that endocrine therapies may have a more modest effect on vaccine-mediated immunity (45) . In our trial, all patients in cohort 2 were receiving concurrent HER2 targeted treatments, while only 2 had received endocrine therapies. Intriguingly, all patients receiving T-DM1 that were analyzed by CyTOF (n=3, Sup Table S2 ) were in the group with increased perforin expression following VRP-HER2 vaccination. Concurrent T-DM1 has been shown to improve responses to ICB pre-clinically (46), thus assessing this trend will be of significant interest in our future studies.
Despite the difficulty of measuring HER2-specific antibodies in a population of patients receiving trastuzumab treatment, we developed assays that demonstrate the presence of vaccineinduced HER2-specific antibodies with multiple effector functions ( Figure 3 
combination of two HER2 targeted antibodies provides greater clinical benefit (3), a vaccine strategy that broadens the anti-HER2 antibody response to increase both the epitopes that are recognized and the effector functions elicited, as we have demonstrated here, has the potential to limit immune escape and resistance. While we were able to detect functional antibodies in vaccinated patients, high background and patient specific variability in addition to our small sample sizes limit our ability to extrapolate these results and link them to survival advantages.
We will continue to monitor the relationship between polyfunctional antibody responses and favorable clinical outcomes in our future studies.
Clinically, VRP-HER2 was well tolerated and there were no dose limiting toxicities when it was given alone or in conjunction with other HER2-targeting therapies. The majority of AEs that occurred during this trial were grade 1 or 2. There were three grade 3 AEs, though none were felt related to VRP-HER2. There was one partial response and stable disease in seven patients in cohort 2, with continued stable disease in two patients at the time of manuscript submission.
Median PFS in both the VRP-HER2 only cohort and the VRP-HER2 + anti-HER2 therapy cohort was modest at 1.8 and 3.6 months respectively; however, median OS was 50.2 months in cohort 1 and 32.7 months in cohort 2. This dichotomy in early progression but long-term survival may suggest that the immune response to vaccination which eventually results in clinical benefit is slow to develop and that overall survival is a better metric of efficacy of this vaccine strategy.
In considering how our clinical results compare against similar published studies, the most comparable published study is the TH3RESA study (TDM-1 vs physicians' choice) (48). Both studies enrolled HER2+ patients with a median of >3 prior lines of HER2 directed systemic therapy. The median OS of 32.7 months for our study compares favorably to the median OS of 22.7 months seen in the TH3RESA study. Importantly, the subset of patients with the greatest expansion of functional HER2-specific T cells in response to vaccination correlated with improved PFS (p=0.04), suggesting that readouts of immune activation may also be a useful marker for efficacy ( Figure 4B ). In addition, there was an overall survival advantage seen in patients that had a decrease in peripheral Tregs following vaccination (Sup Figure S5B) . The small sample size of this clinical trial limits its extrapolation and prompted us to begin a larger Phase II study to validate and extend these findings.
This phase I study supported the hypothesis that we can expand HER2-specific T cells in patients with advanced HER2 overexpressing breast cancer. Both our pre-clinical and clinical data using this vaccine demonstrated the expansion of a HER2-specific, cytolytic CD8 T cell population ( Figures 1E and 2C) . Importantly, the expansion of the perforin+ subset also correlates with improved PFS ( Figure 4B 7 IU in the footpad. Two weeks post-vaccination spleen and serum was taken and analyzed. (N=4 mice/group) A.) Splenocytes were stimulated with empty VRP vector or a pool of HER2 peptides and IFN-γ producing cells were analyzed by ELISPOT. B.) Serum was analyzed for HER2-specific antibodies using a cell-based ELISA. Absorbances are corrected for signal seen in a negative control plate. C.) MM3MG-HER2 tumor cells were implanted into the mammary fat pad of mice. Preventative vaccines were given 2 weeks prior to implantation and therapeutic vaccines were given 1 day post tumor implantation. Mice that completely cleared tumors were rechallenged on the opposite side in the mammary fat pad on day 35. Tumors were measured biweekly. (n=5 mice/group) D.) Splenocytes from mice in (C) were stimulated with a pool of HER2 peptides and IFN-γ producing cells were analyzed by ELISPOT. E.) Splenocytes from mice in (C) following rechallenge were incubated with brefeldin A alone or a mixture of HER2 peptides and CD107a/b antibodies to measure degranulation by flow cytometry. Cells were pregated on live CD45+ CD8+ CD44hi prior to analysis of CD107a/b expression. F.) Serum from mice in (C) was analyzed for HER2-specific antibodies using a cell-based ELISA. 
